French Plans to Cut Spending Through Off-label Medicines Jeopardizes Patient Safety and Challenges EU Regulatory Standards
The European Confederation of Pharmaceutical Entrepreneurs is very concerned about legislative developments on the use of off-label medicines in France.
The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) is very concerned about legislative developments on the use of off-label medicines in France. This week, the lower house of the French Parliament, the Assemblée nationale, voted on a draft law which would broaden the use of off-label medicines, even if on-label medicines are available. The proposal, which explicitly aims reducing the health insurance system’s spending, has now to be approved by the upper house of Parliament, the Sénat, before being formally adopted.
While the off-label use of medicines is appropriate for medical reasons – for example in pediatric care when no on-label treatment is available – concerns are growing that European doctors are being pushed to prescribe off-label medicines to reduce spending. Medicines used off-label are not systematically tested to the same stringent standards for the off-label indication that is required for authorized medicines. Member States promoting off-label use purely for economic reasons therefore put patients at unnecessary risk.
Furthermore, the promotion of off-label use for economic reasons undermines the innovative potential of all pharmaceutical companies in Europe and especially in France. In particular, small to medium-sized companies and those developing orphan medicinal products for rare diseases will be impacted by these developments. The French law counteracts ongoing efforts funded by Member States to boost innovation and research in Europe.
EUCOPE Secretary General Alexander Natz said: “The proposed French legislation not only conflicts with EU law and poses a significant impediment to our highly innovative members but most importantly puts patients at risk. We therefore call on the European Commission to stop national developments infringing EU law. We must adhere to the highest standards of patient safety enshrined in the EU’s regulatory framework and have to ensure that the use of medicines is driven by patients’ medical needs rather than budget considerations.”
For questions please contact [email protected]
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
